Ocugen has commenced a Phase lll clinical trial to evaluate OCU310 for the treatment of patients with dry eye disease (DED).

The placebo-controlled trial aims to enrol around 240 patients and is expected to analyse the efficacy and safety results after 28 days of treatment.

The trial’s primary endpoints are change from baseline to four weeks or on Day 28 in Symptom Assessment iN Dry Eye (SANDE) score and the change from baseline to four weeks or at Day 28 as measured by lissamine green conjunctival staining scores.

Top-line data from the trial is expected to be released in the second half of next year.

Ocugen chairman, CEO and co-founder Shankar Musunuri said: “OCU310 has the potential to improve the signs and symptoms in patients with DED as early as 28 days as opposed to existing therapies.”

“OCU310 has the potential to improve the signs and symptoms in patients with DED as early as 28 days as opposed to existing therapies.”

OCU310, Ocugen’ second lead product candidate, is a twice-daily, steroid-free, preservative-free eye drop of 0.2% brimonidine tartrate developed using the company’s nanoemulsion technology, OcuNanoE.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is currently being developed for treating the signs and symptoms of DED, a common ocular disorder involving the abnormal production, composition and instability of tear film.

Earlier this year, Ocugen concluded a Phase ll clinical trial of OCU310 in patients with  DED.

In the placebo-controlled proof-of-concept trial, the patients were dosed with brimonidine tartrate (0.2%) twice a day for 84 days.

The trial met its endpoint of tolerability, as well as various other pre-defined exploratory endpoints for common signs and symptoms of DED, thereby supporting the range of endpoints for the Phase lll trial.